Yes, disappointing. there seems to be no end to the selling.the fact that deadlines on the Vanuatu project seem to be missed repeatedly could account for the lack of faith in the company.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%